Cargando…

Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models

Imaging of clinically relevant preclinical animal models is critical to the development of personalized therapeutic strategies for endometrial carcinoma. Although orthotopic patient-derived xenografts (PDXs) reflecting heterogeneous molecular subtypes are considered the most relevant preclinical mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Fonnes, Tina, Strand, Elin, Fasmer, Kristine E., Berg, Hege F., Espedal, Heidi, Sortland, Kristina, Stefansson, Ingunn, Bjørge, Line, Haldorsen, Ingfrid S., Krakstad, Camilla, McCormack, Emmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072497/
https://www.ncbi.nlm.nih.gov/pubmed/32041116
http://dx.doi.org/10.3390/cancers12020370
_version_ 1783506420407205888
author Fonnes, Tina
Strand, Elin
Fasmer, Kristine E.
Berg, Hege F.
Espedal, Heidi
Sortland, Kristina
Stefansson, Ingunn
Bjørge, Line
Haldorsen, Ingfrid S.
Krakstad, Camilla
McCormack, Emmet
author_facet Fonnes, Tina
Strand, Elin
Fasmer, Kristine E.
Berg, Hege F.
Espedal, Heidi
Sortland, Kristina
Stefansson, Ingunn
Bjørge, Line
Haldorsen, Ingfrid S.
Krakstad, Camilla
McCormack, Emmet
author_sort Fonnes, Tina
collection PubMed
description Imaging of clinically relevant preclinical animal models is critical to the development of personalized therapeutic strategies for endometrial carcinoma. Although orthotopic patient-derived xenografts (PDXs) reflecting heterogeneous molecular subtypes are considered the most relevant preclinical models, their use in therapeutic development is limited by the lack of appropriate imaging modalities. Here, we describe molecular imaging of a near-infrared fluorescently labeled monoclonal antibody targeting epithelial cell adhesion molecule (EpCAM) as an in vivo imaging modality for visualization of orthotopic endometrial carcinoma PDX. Application of this near-infrared probe (EpCAM-AF680) enabled both spatio-temporal visualization of development and longitudinal therapy monitoring of orthotopic PDX. Notably, EpCAM-AF680 facilitated imaging of multiple PDX models representing different subtypes of the disease. Thus, the combined implementation of EpCAM-AF680 and orthotopic PDX models creates a state-of-the-art preclinical platform for identification and validation of new targeted therapies and corresponding response predicting markers for endometrial carcinoma.
format Online
Article
Text
id pubmed-7072497
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70724972020-03-19 Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models Fonnes, Tina Strand, Elin Fasmer, Kristine E. Berg, Hege F. Espedal, Heidi Sortland, Kristina Stefansson, Ingunn Bjørge, Line Haldorsen, Ingfrid S. Krakstad, Camilla McCormack, Emmet Cancers (Basel) Article Imaging of clinically relevant preclinical animal models is critical to the development of personalized therapeutic strategies for endometrial carcinoma. Although orthotopic patient-derived xenografts (PDXs) reflecting heterogeneous molecular subtypes are considered the most relevant preclinical models, their use in therapeutic development is limited by the lack of appropriate imaging modalities. Here, we describe molecular imaging of a near-infrared fluorescently labeled monoclonal antibody targeting epithelial cell adhesion molecule (EpCAM) as an in vivo imaging modality for visualization of orthotopic endometrial carcinoma PDX. Application of this near-infrared probe (EpCAM-AF680) enabled both spatio-temporal visualization of development and longitudinal therapy monitoring of orthotopic PDX. Notably, EpCAM-AF680 facilitated imaging of multiple PDX models representing different subtypes of the disease. Thus, the combined implementation of EpCAM-AF680 and orthotopic PDX models creates a state-of-the-art preclinical platform for identification and validation of new targeted therapies and corresponding response predicting markers for endometrial carcinoma. MDPI 2020-02-06 /pmc/articles/PMC7072497/ /pubmed/32041116 http://dx.doi.org/10.3390/cancers12020370 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fonnes, Tina
Strand, Elin
Fasmer, Kristine E.
Berg, Hege F.
Espedal, Heidi
Sortland, Kristina
Stefansson, Ingunn
Bjørge, Line
Haldorsen, Ingfrid S.
Krakstad, Camilla
McCormack, Emmet
Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models
title Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models
title_full Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models
title_fullStr Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models
title_full_unstemmed Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models
title_short Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models
title_sort near-infrared fluorescent imaging for monitoring of treatment response in endometrial carcinoma patient-derived xenograft models
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072497/
https://www.ncbi.nlm.nih.gov/pubmed/32041116
http://dx.doi.org/10.3390/cancers12020370
work_keys_str_mv AT fonnestina nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels
AT strandelin nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels
AT fasmerkristinee nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels
AT berghegef nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels
AT espedalheidi nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels
AT sortlandkristina nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels
AT stefanssoningunn nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels
AT bjørgeline nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels
AT haldorseningfrids nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels
AT krakstadcamilla nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels
AT mccormackemmet nearinfraredfluorescentimagingformonitoringoftreatmentresponseinendometrialcarcinomapatientderivedxenograftmodels